Trastuzumab administration during pregnancy: un update
Abstract Background Over than one third (28–58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors....
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2021-04-01
|
| Серии: | BMC Cancer |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1186/s12885-021-08162-3 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|